Skip to main content

9th Circ. Securities Fraud Ruling Bodes Well For Pharma Cos.

Mintz Members Douglas Baumstein and Jason Vigna co-authored a Law360 article discussing the 9th Circuit securities fraud ruling that benefits clinical-stage pharmaceutical companies and companies that are the target of short-seller attacks. The article summarizes, "the U.S. Court of Appeals for the Ninth Circuit recently issued an opinion in In re: Nektar Therapeutics Securities Litigation, affirming dismissal of a securities fraud complaint against the company and certain officers".